Variable	Confirmed case N = 1,034	Not confirmed N = 1,485	p-valu
HIV status, n (%)			<0.00
Person with HIV	292 (86%)	634 (94%)	
Person without HIV	37 (11%)	37 (5.5%)	
Unknown	10 (2.9%)	1 (0.1%)	
Missing/Unknown	695	813	
ever hospitalized, n (%)			0.6
Yes	99 (93%)	76 (90%)	
No	7 (6.6%)	8 (9.5%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	928	1,401	
Length of hospitalization, Median (Q1, Q3)	8.0 (5.0, 13.0)	7.0 (5.0, 11.0)	0.6
Missing/Unknown	969	1,424	
Escalation of care, n (%)			>0.9
Yes	1 (1.9%)	1 (3.4%)	
No	52 (98%)	28 (97%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	981	1,456	
supplemental oxygen, n (%)			0.6
Yes	0 (0%)	1 (3.4%)	
No	52 (98%)	28 (97%)	
Unknown	1 (1.9%)	0 (0%)	
Missing/Unknown	981	1,456	
receive nasogastric fluids, n (%)			>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	37 (100%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
receive IV fluids during course monkeypox infection, n (%)			0.4
Yes	5 (8.3%)	1 (2.7%)	
No	55 (92%)	36 (97%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
receive analgesia for pain management, n (%)			0.00
Yes	33 (55%)	8 (22%)	
No	27 (45%)	29 (78%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	

Variable	Confirmed case N = 1,034	Not confirmed N = 1,485	p-value
receive antibiotics during course monkeypox infection, n (%)			0.5
Yes	56 (93%)	33 (89%)	
No	4 (6.7%)	4 (11%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
receive antifungals during course monkeypox infection, n (%)			>0.9
Yes	1 (1.7%)	0 (0%)	
No	59 (98%)	37 (100%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
experimental antiviral during course monkeypox infection, n (%)			>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	37 (100%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	